FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990166265> ?p ?o ?g. }

• W2990166265 abstract "Introduction: Acoustic Cluster Therapy (ACT) comprises coadministration of a formulation containing microbubble-microdroplet clusters (PS101) together with a regular medicinal drug and local ultrasound (US) insonation of the targeted pathological tissue. PS101 is confined to the vascular compartment and when the clusters are exposed to regular diagnostic imaging US fields, the microdroplets undergo a phase shift to produce bubbles with a median diameter of 22 µm. Low frequency, low mechanical index US is then applied to drive oscillations of the deposited ACT bubbles to induce biomechanical effects that locally enhance extravasation, distribution, and uptake of the coadministered drug, significantly increasing its therapeutic efficacy. Methods: The therapeutic efficacy of ACT with irinotecan (60 mg/kg i.p.) was investigated using three treatment sessions given on day 0, 7, and 14 on subcutaneous human colorectal adenocarcinoma xenografts in mice. Treatment was performed with three back-to-back PS101+US administrations per session with PS101 doses ranging from 0.40-2.00 ml PS101/kg body weight (n = 8-15). To induce the phase shift, 45 s of US at 8 MHz at an MI of 0.30 was applied using a diagnostic US system; low frequency exposure consisted of 1 or 5 min at 500 kHz with an MI of 0.20. Results: ACT with irinotecan induced a strong, dose dependent increase in the therapeutic effect (R2 = 0.95). When compared to irinotecan alone, at the highest dose investigated, combination treatment induced a reduction in average normalized tumour volume from 14.6 (irinotecan), to 5.4 (ACT with irinotecan, p = 0.002) on day 27. Median survival increased from 34 days (irinotecan) to 54 (ACT with irinotecan, p = 0.002). Additionally, ACT with irinotecan induced an increase in the fraction of complete responders; from 7% to 26%. There was no significant difference in the therapeutic efficacy whether the low frequency US lasted 1 or 5 min. Furthermore, there was no significant difference between the enhancement observed in the efficacy of ACT with irinotecan when PS101+US was administered before or after irinotecan. An increase in early dropouts was observed at higher PS101 doses. Both mean tumour volume (on day 27) and median survival indicate that the PS101 dose response was linear in the range investigated." @default.
• W2990166265 created "2019-12-05" @default.
• W2990166265 creator A5007923764 @default.
• W2990166265 creator A5026297799 @default.
• W2990166265 creator A5047822861 @default.
• W2990166265 creator A5051107742 @default.
• W2990166265 creator A5061652565 @default.
• W2990166265 creator A5068598538 @default.
• W2990166265 creator A5072603201 @default.
• W2990166265 creator A5083770972 @default.
• W2990166265 creator A5085674047 @default.
• W2990166265 date "2019-11-19" @default.
• W2990166265 modified "2023-09-23" @default.
• W2990166265 title "Therapeutic Dose Response of Acoustic Cluster Therapy in Combination With Irinotecan for the Treatment of Human Colon Cancer in Mice" @default.
• W2990166265 cites W1749344609 @default.
• W2990166265 cites W1959988533 @default.
• W2990166265 cites W1964875797 @default.
• W2990166265 cites W1970179483 @default.
• W2990166265 cites W2002440649 @default.
• W2990166265 cites W2002516695 @default.
• W2990166265 cites W2011048803 @default.
• W2990166265 cites W2014952014 @default.
• W2990166265 cites W2022654795 @default.
• W2990166265 cites W2041885437 @default.
• W2990166265 cites W2058123495 @default.
• W2990166265 cites W2066153482 @default.
• W2990166265 cites W2067242125 @default.
• W2990166265 cites W2070672521 @default.
• W2990166265 cites W2088181795 @default.
• W2990166265 cites W2115785123 @default.
• W2990166265 cites W2125922770 @default.
• W2990166265 cites W2129674968 @default.
• W2990166265 cites W2136828611 @default.
• W2990166265 cites W2138215047 @default.
• W2990166265 cites W2145394581 @default.
• W2990166265 cites W2159241744 @default.
• W2990166265 cites W2187153308 @default.
• W2990166265 cites W2239845546 @default.
• W2990166265 cites W2274892987 @default.
• W2990166265 cites W2414605226 @default.
• W2990166265 cites W2433010802 @default.
• W2990166265 cites W2480845735 @default.
• W2990166265 cites W2499317692 @default.
• W2990166265 cites W2515625409 @default.
• W2990166265 cites W2534733043 @default.
• W2990166265 cites W2549613229 @default.
• W2990166265 cites W2551147446 @default.
• W2990166265 cites W2556034722 @default.
• W2990166265 cites W2793045391 @default.
• W2990166265 cites W2954764244 @default.
• W2990166265 doi "https://doi.org/10.3389/fphar.2019.01299" @default.
• W2990166265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6877694" @default.
• W2990166265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31803049" @default.
• W2990166265 hasPublicationYear "2019" @default.
• W2990166265 type Work @default.
• W2990166265 sameAs 2990166265 @default.
• W2990166265 citedByCount "11" @default.
• W2990166265 countsByYear W29901662652019 @default.
• W2990166265 countsByYear W29901662652020 @default.
• W2990166265 countsByYear W29901662652021 @default.
• W2990166265 countsByYear W29901662652022 @default.
• W2990166265 countsByYear W29901662652023 @default.
• W2990166265 crossrefType "journal-article" @default.
• W2990166265 hasAuthorship W2990166265A5007923764 @default.
• W2990166265 hasAuthorship W2990166265A5026297799 @default.
• W2990166265 hasAuthorship W2990166265A5047822861 @default.
• W2990166265 hasAuthorship W2990166265A5051107742 @default.
• W2990166265 hasAuthorship W2990166265A5061652565 @default.
• W2990166265 hasAuthorship W2990166265A5068598538 @default.
• W2990166265 hasAuthorship W2990166265A5072603201 @default.
• W2990166265 hasAuthorship W2990166265A5083770972 @default.
• W2990166265 hasAuthorship W2990166265A5085674047 @default.
• W2990166265 hasBestOaLocation W29901662651 @default.
• W2990166265 hasConcept C102652120 @default.
• W2990166265 hasConcept C110121322 @default.
• W2990166265 hasConcept C121608353 @default.
• W2990166265 hasConcept C126322002 @default.
• W2990166265 hasConcept C126838900 @default.
• W2990166265 hasConcept C126894567 @default.
• W2990166265 hasConcept C134306372 @default.
• W2990166265 hasConcept C138010386 @default.
• W2990166265 hasConcept C142724271 @default.
• W2990166265 hasConcept C143753070 @default.
• W2990166265 hasConcept C19831878 @default.
• W2990166265 hasConcept C2779540182 @default.
• W2990166265 hasConcept C2780035454 @default.
• W2990166265 hasConcept C2780259306 @default.
• W2990166265 hasConcept C33923547 @default.
• W2990166265 hasConcept C526805850 @default.
• W2990166265 hasConcept C64012434 @default.
• W2990166265 hasConcept C71924100 @default.
• W2990166265 hasConcept C98274493 @default.
• W2990166265 hasConceptScore W2990166265C102652120 @default.
• W2990166265 hasConceptScore W2990166265C110121322 @default.
• W2990166265 hasConceptScore W2990166265C121608353 @default.
• W2990166265 hasConceptScore W2990166265C126322002 @default.
• W2990166265 hasConceptScore W2990166265C126838900 @default.
• W2990166265 hasConceptScore W2990166265C126894567 @default.
• W2990166265 hasConceptScore W2990166265C134306372 @default.
• W2990166265 hasConceptScore W2990166265C138010386 @default.

• next